Ben Fidler

The setback likely removes one competitor to an emerging spinal muscular atrophy medicine from Scholar Rock, but sets the stage for a pair of readouts with implications for weight loss research.

While early and from a small trial, the findings suggest Janux's method of “masking” T cell engagers could lead to differentiated results, some analysts said.

The firm’s co-founders claim to be pursuing a “contrarian” approach, building a team versed in both computing and life sciences and concentrating resources on a smaller number of bets.

J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH mid-stage findings for important new medicines.

The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned class of heart medicines called CETP inhibitors.

The agency identified 20 cases of serious liver damage associated with Ocaliva in the latest setback for a drug once seen as a potential blockbuster.

Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and Roche, each of which were acquired in multibillion-dollar deals.

In This Article AKESF This story was originally published on BioPharma Dive . To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter

Vertex's new cystic fibrosis medicine could help extend the company's market dominance, while Bristol Myers aims to capitalize on a more convenient formulation of its Opdivo immunotherapy.

Every presidential election brings change to the Food and Drug Administration. This time around, the upheaval could be particularly jarring.